Google is moving from a “mobile first” world to an “AI first” one within health, CBInsights reports
Google has been leading the way within the healthcare industry. Although its efforts have not been widely popularised in comparison to Apple or Amazon, the company has an acute awareness that the industry is ripe for disruption.
Launching a number of subsidiaries back in 2015, Google has strenuously worked to develop new digital tools to cater to growing consumer demand for increasingly connected care which will improve efficiencies and positive patient outcomes.
Whilst its subsidiary Verily has become focused on utilising data to improve healthcare through the use of new analytical tools, its DeepMind division is supporting Google’s drive to become a leader in the AI space, and find new ways in which AI can be adopted in healthcare to provide new insights and enable further opportunities to innovate. Thirdly, its Calico division is working to adopt solutions within age-related diseases.
The technology giant has become one of the leading investors, and an active investor and acquirer of AI companies, a report by CBInsights has found.
“If AI can shape healthcare, it has to work through the regulations of healthcare. In fact, I see that as one of the biggest areas where the benefits will play out for the next 10-20 years,” Google’s Chief Executive Officer, Sundar Pichai has said.
Google’s subsidiary, DeepMind, is working within the Ai space and is set to overhaul the efficiency of present clinical systems. Undertaking AI research with the NHS in the United Kingdom in 2016, the subsidiary is also working with University College London to implement AI into traditional cancer treatment, the report has noted.
Additionally, it has also partnered with MoorfieldsEeye Hospital to transform the use of traditional eye scans.
Traditional clinical systems have been unable to migrate effectively. Breakdowns in communication from provider to provider has negatively impacted the patient experience, something of which is becoming increasingly significant as a result of a consumer demand for bespoke solutions.
DeepMind is therefore looking to overhaul such barriers in the industry by implementing of a new healthcare standard, named Fast Healthcare Interoperability Resources (FHIR). This will support the establishment of a new, connected care pathway and deliver care with is second to none.
From 2013-2017, digital healthcare deals under Google Ventures has now risen to over 70.
By looking at enhance its healthcare delivery through looking at ways to identify, diagnosis and manage diseases at a quicker pace, Verily has invested in a number of healthcare, pharmaceutical and biotech companies. Its $300mn investment within the EU Biotech Fund in June 2017 and its funding of biotech start-up XtalPi, undertaken with Tencent and Sequoia, are a couple of note.
- Trump reveals his tough stance on tackling the opioid crisis, which is swiftly panned by experts
- The medical technology industry is set to be worth over $460bn by 2020
- There is an urgent need and a huge opportunity to embrace Life Sciences 4.0, report claims
Additionally, it has established the Verily Partner Space to support start-ups and encourage entrepreneurs to meet their potential. This has become aligned to the subsidiary’s investment in a number of specialised areas across its research operations.
Partnering with biopharma company Sanofi has seen the establishment of joint venture Onduo, which will focus on delivering comprehensive solutions. This will involve combining devices, software, medicine and professional care within disease management.
Merging its technical expertise with Sanofi’s clinical knowledge, the two companies will create exceptional treatments to those living with type 2 diabetes. Over time, Onduo will move its focus to develop solutions for those with type 1 diabetes.
Sutter Health of Northern California and Allegheny Health Network of western Pennsylvania are among the first healthcare networks to collaborate with Verily and Onduo to test the platform with healthcare professionals and people with type 2 diabetes in a clinical care setting.
Allegheny Health Network is an academic healthcare system consisting of eight hospitals, outpatient surgery centres, health and wellness pavilions, a research institute and more than 1,100 employed physicians.
"With Onduo, Sanofi and Verily are bringing forward a platform that is novel and critical in diabetes management," commented Steven V. Edelman, M.D., Founder and Director of TCOYD. "Onduo is a company focused on the improvement of health outcomes through the marriage of technology and medicine.
Through various partnerships, Verily is placing significant focus in a number of other areas. Such examples are its research into the development of implantable eye devices to support those with weakened eyesight, as well the development of solutions for those with Parkinson’s and Multiple Sclerosis.
Partnering with GlaxoSmithKline will enable the company to create a way to control how electrical signals flow throughout the body for those with multiple sclerosis. Its efforts will support patients with their posture, and even halt the disease, the report has found.
Additionally, Verily’s collaboration with Johnson & Johnson has seen it develop robots to support complex surgeries.
Furthermore, Verily’s “One Brave Idea” has seen Verily work within the detection, prevention and possible reversal of coronary heart disease.
Whilst Google provides G Suite for healthcare professionals, it will increasingly look at new ways to promote collaboration and the sharing of data through the use of new technologies, implementing robust security measures in the process.
It will also promote transparency through the adoption of open-source tools for researchers across a number of specialist areas, e.g. genomics.
Skin Analytics wins NHSX award for AI skin cancer tool
An artificial intelligence-driven tool that identifies skin cancers has received an award from NHSX, the NHS England and Department of Health and Social Care's initiative to bring technology into the UK's national health system.
NHSX has granted the Artificial Intelligence in Health and Care Award to DERM, an AI solution that can identify 11 types of skin lesion.
Developed by Skin Analytics, DERM analyses images of skin lesions using algorithms. Within primary care, Skin Analytics will be used as an additional tool to help doctors with their decision making.
In secondary care, it enables AI telehealth hubs to support dermatologists with triage, directing patients to the right next step. This will help speed up diagnosis, and patients with benign skin lesions can be identified earlier, redirecting them away from dermatology departments that are at full capacity due to the COVID-19 backlog.
Cancer Research has called the impact of the pandemic on cancer services "devastating", with a 42% drop in the number of people starting cancer treatment after screening.
DERM is already in use at University Hospitals Birmingham and Mid and South Essex Health & Care Partnership, where it has led to a significant reduction in unnecessary referrals to hospital.
Now NHSX have granted it the Phase 4 AI in Health and Care Award, making DERM available to clinicians across the country. Overall this award makes £140 million available over four years to accelerate the use of artificial intelligence technologies which meet the aims of the NHS Long Term Plan.
Dr Lucy Thomas, Consultant Dermatologist at Chelsea & Westminster Hospital, said: “Skin Analytics’ receipt of this award is great news for the NHS and dermatology departments. It will allow us to gather real-world data to demonstrate the benefits of AI on patient pathways and workforce challenges.
"Like many services, dermatology has severe backlogs due to the COVID-19 pandemic. This award couldn't have come at a better time to aid recovery and give us more time with the patients most in need of our help.”